OBS! Sista ansökningsdag har passerat för denna annons. Du kan fortfarande läsa om den, men det går inte längra att ansöka.
The BioInvent team covers all aspects of drug development, including discovery, preclinical and translational research, manufacturing, and clinical development.
Together we are creating the exciting future of BioInvent, and we welcome you to be part of it as
Experienced Drug Supply Manager
to BioInvent´s Clinical Development Team
Main Responsibilities
As Drug Supply Manager you will manage clinical study drug activities across studies and projects according to timelines and company milestones, including but not limited to:
Qualifications
We are looking for a driven, structured, self-motivated, independent, and responsible person, who understands complex projects and interdependencies and easily collaborates and communicates with others both verbally and in writing. You have excellent problem solving and negotiation skills and you enjoy creating efficient working methods and contributing with your experience to ensure continuous improvements.
Personal suitability is of great importance, we nurture a culture of teamwork, positive team spirit and promote the development of each member in the team. We believe that you are efficient, have a strong commitment and ability to make things happen. You understand the importance of achieving results, keeping deadlines, and securing high quality within your work. You are enthusiastic and enjoy creating results and achieving goals both individually and together with your teams.
The position is office-based in Lund. However, the position may also offer a flexible working arrangement.
Starting Date: as soon as possible
Application
BioInvent has several value driving factors in place with great potential for the future. If you match the described profile and would like to contribute to important cancer research, you are welcome to apply for the position!
Please send us your application, personal letter and CV and tell us why you are the right person for this position, at the latest 7th of April 2024.